| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.2 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.38 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |